Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

26% Objective Response Rate 

Median Duration of Response Not Reached after 25 Months Follow Up

Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027

Read more at globenewswire.com